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Intravital ﬂuorescence microscopyInﬂammatory endothelial processes are regulated by the nuclear factor-κB (NF-κB) pathway, which involves
phosphorylation of p65. Because p65 is a substrate of CK2, we herein investigated, whether this pleiotropic
protein kinase may be a beneﬁcial anti-inﬂammatory target. For this purpose, we analyzed in human dermal
microvascular endothelial cells (HDMEC) the effect of CK2 inhibition by quinalizarin and CX-4945 on cell
viability, adhesion molecule expression and NF-κB pathway activation. Leukocyte binding to HDMEC was
assessed in an in vitro adhesion assay. Dorsal skinfold chambers in BALB/c mice were used to study leukocyte–
endothelial cell interaction and leukocyte transmigration bymeans of repetitive intravitalﬂuorescencemicrosco-
py and immunohistochemistry. We found that quinalizarin and CX-4945 effectively suppressed the activity of
CK2 in HDMEC without affecting their viability. This was associated with a signiﬁcant down-regulation of
tumor necrosis factor (TNF)-α-induced E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell
adhesionmolecule (VCAM)-1 expression due to a reduction of shuttling, phosphorylation and transcriptional ac-
tivity of the NF-κB complex. In consequence, leukocyte binding to quinalizarin- and CX-4945-treated HDMEC
was diminished. Finally, CX-4945 treatment signiﬁcantly decreased the numbers of adherent and transmigrated
leukocytes in dorsal skinfold chambers exposed to TNF-α in vivo. These ﬁndings indicate that CK2 is a key
regulator of leukocyte–endothelial cell interaction in inﬂammation by regulating the expression of E-selectin,
ICAM-1 and VCAM-1 via affecting the transcriptional activity of the NF-κB complex. Accordingly, CK2 represents
a promising target for the development of novel anti-inﬂammatory drugs.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Leukocyte–endothelial cell interaction is a key process in tumor
necrosis factor (TNF)-α-induced inﬂammation and is characterized by
a coordinated sequence of adhesive interactions between leukocytes
and the microvascular endothelium [1,2]. Upon TNF-α stimulation,
activated endothelial cells express different cell adhesion proteins on
their surface. These include selectins, such as E-selectin, which promote
leukocyte rolling along the endothelial lining [3] and members of the
immunoglobulin superfamily, such as intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesionmolecule (VCAM)-1, whichmediate
ﬁrm leukocyte adhesion to the endothelium [4,5]. Firm adhesion is a
major prerequisite for the subsequent transendothelial migration of
leukocytes into inﬂamed tissue [6].
A fundamental TNF-α-induced cellular pathway, which mediates
the expression of E-selectin, ICAM-1 and VCAM-1 during inﬂammatory
conditions, involves signaling via nuclear factor-κB (NF-κB) [7]. In non-o).stimulated cells, the transcription factor p65, which is a component of
the heterodimeric NF-κB complex, is sequestered by IκBα proteins in
the cytoplasm [8,9]. Under stimulation with TNF-α, these IκBα proteins
are phosphorylated and subsequently degraded. This degradation
promotes the translocation of p65 from the cytoplasm into the nucleus,
where it acts as a transcriptional activator for E-selectin, ICAM-1 and
VCAM-1 [10–13].
The transcriptional activity of p65 is dependent on its phosphoryla-
tion, which is regulated by a variety of different kinases, including pro-
tein kinase CK2, formerly known as casein kinase II [14,15]. The CK2
holoenzyme is a tetramer consisting of two catalytic subunits CK2α
and CK2α′ and two non-catalytic subunits CK2β [16]. The consensus
sequence contains serine or threonine residues surrounded by acidic
amino acids [17]. This kinase is involved in various cellular processes,
including proliferation, differentiation, apoptosis and angiogenesis
[18–21]. However, the speciﬁc function of CK2on leukocyte–endothelial
cell interaction during TNF-α-induced inﬂammation remains elusive.
Therefore, the aim of the present study was to analyze in vitro the
effect of CK2 inhibition on i) endothelial expression of E-selectin, ICAM-
1 and VCAM-1, ii) subcellular localization and transcriptional activity of
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addition, dorsal skinfold chamberswere prepared in BALB/cmice, treated
with CX-4945 or vehicle, to study in vivo the effect of CK2 inhibition on
TNF-α-up-regulated leukocyte–endothelial cell interaction and leukocyte
transmigration by means of repetitive intravital ﬂuorescence microscopy
and immunohistochemistry.
2. Materials and methods
2.1. Chemical and biological reagents
Endothelial Cell Basal Medium (C-22210) was purchased from
PromoCell (Heidelberg, Germany), γ[32P]ATP from Hartmann Ana-
lytic (Braunschweig, Germany), human TNF-α from Provitro (Berlin,
Germany), murine TNF-α from PeproTech (Hamburg, Germany),
calcein-AM from Molecular Probes (Eugene, OR, USA), CX-4945 from
AdooQ (Irvine, CA, US), quinalizarin, hexadimethrine bromide, ﬂuoresce-
in isothiocyanate (FITC)-labeled dextran 150,000 and rhodamine 6G
fromSigma-Aldrich (München, Germany), a set of three small interfering
RNA (siRNA) duplexes directed against CK2α, CK2α′ and non-targeting
siRNA control (ON-TARGET plus SMARTpools) from Dharmacon/GE
Healthcare (Germany), HiPerFect transfection reagent from Qiagen
(Hilden, Germany), 4′,6-diamidino-2′-phenylindole dihydrochloride
(DAPI) from Roche (Mannheim, Germany), Mayer's hemalaun solution
from Merck (Darmstadt, Germany), ketamine (Ursotamin®) fromFig. 1. CX-4945 and quinalizarin decreases CK2 kinase activity without affecting cell viability. (A
or quinalizarin (Q) in the presence of 10 ng/mL TNF-α for 5 h. After cell lysis, CK2 kinase activity
Mean ± SEM. *P b 0.05 vs. vehicle. (B) Expression of CK2α and GAPDH in HDMEC, which wer
representative of experiments conducted in triplicate. (C) Formazan reduction (% of vehicle
(vehicle) or the indicated concentrations of CX-4945 or quinalizarin (Q) for 5 h. Viability wa
which were treated as described in (C) and analyzed by LDH assay. Lysed HDMEC (shaded barPharmacia GmbH (Erlangen, Germany), and xylazine (Rompun®) from
Bayer (Leverkusen, Germany).
2.2. Endothelial cell culture
Human dermal microvascular endothelial cells (HDMEC) were pur-
chased from PromoCell and cultivated in Endothelial Cell Basal Medium
at 37 °C under a humidiﬁed 95% to 5% (v/v) mixture of air and CO2. Cells
were passaged at a split ratio of 1:3 after reaching conﬂuence. All
experiments were carried out with conﬂuent cells between the
third and seventh passage.
2.3. Antibodies
Anti-GAPDH antibody (FL335), anti-α-tubulin antibody (sc-53646),
anti-p65 antibody (sc-372) and anti-phospho-p65 (Ser529) antibody
(sc-101751) were obtained from Santa Cruz Inc. (Heidelberg, Germany).
The antibodies anti-CD54 (ICAM-1) (555511), anti-CD106 (VCAM-1)
(555647), anti-CD31 (platelet endothelial cell adhesion molecule
(PECAM-1)) (555446), anti-CD62E (E-selectin) (551145) and IgG1-κ
Isotype Control (555749) were bought from BD Biosciences (Heidelberg,
Germany). The antibodies anti-CK2α #26 and anti-CK2α′ #30 were
generated as described previously [22]. Peroxidase-labeled anti-rabbit
antibody (NIF 824) and peroxidase-labeled anti-mouse antibody
(NIF 825) were purchased from GE healthcare (Freiburg, Germany).) HDMECwere cultivatedwith DMSO (vehicle) or the indicated concentrations of CX-4945
wasmeasured by CK2 kinase assay. Vehicle treated cellswere used as control and set 100%.
e cultivated as described above and assessed by Western blot analysis. Western blots are
) of HDMEC, which were cultivated without TNF-α, with TNF-α (10 ng/mL) and DMSO
s determined by WST-1 assay. Mean ± SEM. (D) LDH release (% of vehicle) of HDMEC,
) served as high control. Mean ± SEM. *P b 0.05 vs. vehicle.
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ImmunoResearch Laboratories (West Groves, PA, USA). The anti-
myeloperoxidase (MPO) antibody (ab9535) and the secondary bio-
tinylated goat anti-rabbit antibody (ab64256) were obtained from
Abcam (Cambridge, UK).
2.4. CK2 in vitro phosphorylation assay
HDMEC were lysed on ice for 10 min in lysis buffer (RIPA buffer:
50 mM Tris–HCl, pH 7.2, 0.15 M NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0%
Triton X-100, 1.0% sodium deoxycholate). Then, extracts were used for
kinase ﬁlter assays. The incorporation rate of [32P] phosphate into the
CK2-speciﬁc substrate peptide with the sequence RRRDDDSDDD was
measured. 20 μL of kinase buffer (50 mM Tris/HCl, pH 7.5, 100 mM
NaCl, 10 mM MgCl2, 1 mM DTT) containing 30 μg of proteins was
mixed with 30 μL CK2 mix (25 mM Tris-HCl, pH 8.5, 150 mM NaCl,
5 mMMgCl2, 50 μM ATP, 1 mM DTT, 0.19 mM substrate peptide) con-
taining 10 μCi/500 μL γ[32P]ATP. The mixture was spotted onto a P81
ion exchange paper. The paper was washed three times with 85 mM
H3PO4. After treatment with ethanol the paper was dried and the
Čerenkov-radiation was determined in a scintillation counter.
2.5. Water-soluble tetrazolium (WST)-1 assay
AWST-1 assaywas used tomeasure themetabolic activity of treated
HDMEC. In this assay, WST salt is reduced to formazan and the absor-
bance can be measured with a microplate reader at 480 nm. The WST-
1 assay was carried out according to the manufacturer's instructions.
HDMEC were seeded in a 96 well cell culture plate and treated with
10 ng/mL TNF-α in combination with different concentrations of the
CK2 inhibitors quinalizarin or CX-4945 or vehicle (DMSO) in a total vol-
ume of 100 μL for 5 h. Then, 10 μL WST-1 reagent per well was added
and the plate was incubated for 1 h at 37 °C. The absorption was mea-
sured at 480 nm with 620 nm as reference using a microplate reader
and corrected to blank values (wells without cells).
2.6. Lactate dehydrogenase (LDH) assay
A LDH assay (Cytotoxicity Detection KitPLUS, Roche) was used to
analyze the cytotoxicity of the test compounds according to the
manufacturer's instructions. For this purpose, HDMEC were treated as
described above (WST-1 assay). After treatment, 100 μL of LDH-reaction
mix per 100 μL medium was added to each well. After 10 min of incuba-
tion at room temperature in the dark, absorption was measured at
492 nmwith 620 nm as reference after the addition of 50 μL stop solution
using a microplate reader and corrected to blank values (wells without
cells).
2.7. Lentiviral gene transfer and luciferase assay
The lentiviral transfer vector pFWHIVLTRluc that contains the HIV
LTR sequence (sequence from−120 to+83) upstream of the luciferase
open reading frame, has been described recently [23]. Viral particles
were produced as previously described [24] by triple transfection of
293T/17 cells with the gag–pol–rev packaging plasmid, the env plasmid
encoding VSV glycoprotein and the transfer vector. Viral particles were
added to HDMEC seeded in a 24 well cell culture plate (1 mL/well
volume, 90% conﬂuence) for 20 h in the presence of hexadimethrine
(8 μg/mL). Following infection, cells were washed and cultivated in
1 mL/well of Endothelial Cell Basal Medium for 48 h before drug
treatment. Cell extracts were prepared using reporter lysis buffer
(Promega, Mannheim, Germany) and analyzed for luciferase activities.
Luciferase activity was normalized to the protein concentration (relative
luciferase units (RLU)/mg protein).2.8. Western blot analysis
Nuclear and cytoplasmic extracts were prepared as previously
described [25]. Proteins were separated through a 10% SDS polyacryl-
amide gel and transferred onto a PVDF membrane. The membrane
was blocked with 5% dry milk in PBS (0.1% Tween20) for 1 h and then
incubated with the speciﬁc antibodies, which were diluted in PBS
(0.1% Tween20) containing 1% dry milk. The membrane was incubated
with a peroxidase-coupled secondary antibody (anti-rabbit 1:30.000 or
anti-mouse 1:10.000) for 1 h. Protein expression was visualized by
luminol-enhanced chemiluminescence (ECL; GE-Healthcare, Freiburg,
Germany) and exposure of the membranes to a blue light sensitive
autoradiography ﬁlm (Hyperﬁlm ECL, GE-Healthcare).
2.9. siRNA transfection
HDMEC were reversely transfected with siRNA duplexes (100 nM)
directed against CK2α and CK2α′ or with scramble-siRNA as a control,
using HiPerFect transfection reagent for 72 h. The transfection was
refreshed every 24 h. The medium was then removed and the cells
were stimulated with fresh medium containing 10 ng/mL TNF-α for
5 h. Subsequently, the cells were used for ﬂow cytometry or Western
blot analyses.
2.10. Isolation of leukocytes
Venous blood from four human healthy donors was collected into
citrate tubes and 1:1 diluted with PBS. Afterwards, mononuclear cells
(MNC) were isolated on a Ficoll density gradient by centrifugation for
25 min at 1600 rpm. Interphase cells were collected, washed with PBS
by centrifugation for 8 min at 1600 rpm and resuspended in a small
volume of 1× PBS. MNC were counted by a Coulter Counter (AcTdiff,
Coulter, Hamburg, Deutschland) and stained with 500 μL of calcein-
AM (8 μg/mL) for 15 min. Stained cells were washed by centrifugation
for 8 min at 1600 rpm and were used for the adhesion assay.
2.11. Leukocyte adhesion assay
HDMECwere seeded in a 24 well cell culture plate in a total volume
of 1mL/well and allowed to grow to conﬂuence. Then, themediumwas
removed and cells were stimulated with fresh medium containing
10 ng/mL TNF-α in combination with different concentrations of the
CK2 inhibitors or vehicle (DMSO) for 5 h. After that, cells were washed
three times and 1× 105 freshly isolatedMNCwere added and incubated
for 1 h in a total volume of 1mLmedium. After co-cultivation, cells were
gently washed three times in PBS and images of labeled cells that ad-
hered to the HDMEC were taken by ﬂuorescence microscopy (BZ-
8000; Keyence, Osaka, Japan). Stained MNC were counted in two ran-
domly selected microscopic ﬁelds in each well by means of the ImageJ
1.47 software.
2.12. Immunoﬂuorescence microscopy
HDMEC were seeded on coverslips. After 24 h cells were stimulated
withmedium containing 10 ng/mL TNF-α in combinationwith different
concentrations of CX-4945, quinalizarin or DMSO (vehicle) for 5 h.
Then, cells were ﬁxed in PBS with 3.7% paraformaldehyde for 10 min,
permeabilized in PBS with 0.5% Triton X-100 for 10 min and blocked
in PBS with 5% bovine serum albumin (BSA) for 30 min at room
temperature. Afterwards, cells were incubated with the anti-p65 or
anti-phospho-p65 (Ser529) antibodies for 30 min at 37 °C, washed
with 1× PBS and incubated with Cy3-conjugated anti-rabbit antibody
for 30 min at 37 °C. The coverslips were washed and incubated with
DAPI for 30 min at 37 °C. The coverslips were sealed with mounting
media and analyzed by ﬂuorescence microscopy (BX60F; Olympus
Optical, Tokyo, Japan).
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Fig. 3. Silencing of CK2 by siRNA reduces expression of cell adhesionmolecules. (A) HDMECwere treatedwith siRNA against CK2α and CK2α′ or scrambled siRNA for 72 h. Subsequently,
HDMECwere stimulatedwith 10 ng/mL TNF-α for 5 h and the protein levels of CK2α and CK2α′were assessed byWestern blot analysis. Western blots are representative of experiments
conducted in triplicate. (B) CK2/α-tubulin (% of scr-siRNA), as assessed by quantitative analysis of Western blots. Mean ± SEM. *P b 0.05 vs. scr-siRNA. (C–E) HDMEC were treated as
described above and the fold increaseMFI E-selectin (C), ICAM-1 (D) and VCAM-1-positive cells (E) were analyzed by ﬂow cytometry. Scrambled siRNA-treated cells were used as control
and set 100%. Mean ± SEM. *P b 0.05 vs. control.
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HDMEC were seeded in a 24 well cell culture plate in a total vol-
ume of 1 mL/well and allowed to grow to conﬂuence. Then, the me-
dium was removed and cells were stimulated with fresh medium
containing 10 ng/mL TNF-α supplemented with different concentra-
tions of the CK2 inhibitors quinalizarin or CX-4945 or DMSO (vehicle)
for 5 h. Cells were washed and detached by incubation for 15 min at
37 °C with accutase. Subsequently, cells were ﬁxed in PBS containing 1%
formalin for 10 min at 4 °C, washed by centrifugation (1800 ×g for
10 min, RT) in PBS and incubated with the antibodies against E-selectin,
ICAM-1, VCAM-1, PECAM-1 or control antibody (isotype control) for
30 min at room temperature. Thereafter, cells were washed in PBS,
centrifugated and ﬁxed with PBS containing 1% formalin. The ﬂuores-
cence per 5000 cells was analyzed in a FACScan ﬂow cytometer (BectonFig. 2. Inhibition of CK2 affects TNF-α-induced expression of cell adhesionmolecules. (A, C, E, G)
and VCAM-1 expression of HDMEC treated with vehicle (DMSO) and TNF-α (10 ng/mL) for 5
ng/mL) for 5 h. (B, D, F, H) Quantitative analysis of (A, C, E, G). HDMEC were cultivated withou
CX-4945 or quinalizarin (Q) for 5 h. Fold increaseMFI PECAM-1 (B), E-selectin (D), ICAM-1 (F) a
used as control and set 100%. Mean ± SEM. *P b 0.05 vs. vehicle.Dickinson, San Jose, CA, USA) using CellQuest software. Because
unstimulated cells exhibited high levels of PECAM-1, E-selectin
and ICAM-1, the expression of these adhesion molecules was deter-
mined by analyzing the mean ﬂuorescence intensity in the FL2 channel.
In contrast, the expression of VCAM-1 was measured by counting num-
bers of VCAM-1 positive cells.
2.14. Ethics statement
All animal care and experimental procedures were approved by
the local governmental animal care committee (Landesamt für
Verbraucherschutz, Abteilung C Lebensmittel- und Veterinärwesen,
Saarbrücken, Germany; Permit Number: 08/2013) andwere conducted
in accordance with the European legislation on protection of animals
(Guideline 2010/63/EU) and the NIH Guidelines for the Care and UseFlow cytometry histograms: Openhistogramareas represent PECAM-1, E-selectin, ICAM-1
h, ﬁlled histogram areas represent HDMEC treated with CX-4945 (50 μM) and TNF-α (10
t TNF-α, with TNF-α (10 ng/mL) and DMSO (vehicle) or the indicated concentrations of
nd VCAM-1-positive cells (H)were analyzed by ﬂow cytometry. Vehicle treated cells were
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Edition; 2011).
2.15. Dorsal skinfold chamber model
BALB/cmicewith a bodyweight of 20–25 gwere used for the exper-
iments. They were housed in a temperature-controlled environment
under a 12 h/12 h light–dark cycle and received standard pellet food
(Altromin, Lage, Germany) and water ad libitum.
The dorsal skinfold chambermodelwasused to investigate the effect
of CK2 inhibition on leukocyte–endothelial cell interaction in vivo. The
chamber was prepared as described previously in detail [26]. Brieﬂy,
micewere anesthetized by an intraperitoneal (i.p.)mixture of ketamine
(75mg/kg) and xylazine (15mg/kg). Two symmetrical titanium frames
were implanted on the extended dorsal skinfold of the animals, so that
they sandwiched the double layer of the skin. Next, one layer of the skin
was completely removed in a circular area of 15 mm in diameter. The
remaining layers consisting of the epidermis, subcutaneous tissue and
striated skin muscle were covered with a glass coverslip. To avoid alter-
ations of the microcirculation due to anesthesia or surgical trauma, the
mice were allowed to recover for 72 h before the in vivo analyses.
Subsequently, the chamber tissue was topically exposed to 200 ng
murine TNF-α (dissolved in 100 μL saline) to induce a local inﬂammation
[27,28]. To analyze the effect of CK2 inhibition on leukocyte–endothelial
cell interaction, a group of 10 animals was treated with 75 mg/kg CX-
4945 i.p. (dissolved in 50 μL DMSO) 19 h and 1 h before exposure to
TNF-α, whereas 10 vehicle-treated animals served as controls. In addi-
tional experiments, a group of 4 animals was treated again with CX-
4945 or vehicle, as described above. However, the chamber tissue was
topically exposed to saline instead of TNF-α.
2.16. Intravital ﬂuorescence microscopy
For in vivo microscopic observation, mice were immobilized on a
Plexiglas stage and the dorsal skinfold chamber was attached to themi-
croscopic stage. After retrobulbary i.v. injection of 0.05 mL 5% FITC-
dextran 150,000 for contrast enhancement by staining of blood plasma
and 0.05mL0.1% rhodamine 6G for staining of leukocytes, intravital epi-
illumination ﬂuorescence microscopy was performed using a Zeiss
microscope (Zeiss, Oberkochen, Germany) with a 100 W mercury
lamp attached to a blue and green ﬁlter block. The microscopic images
were recorded by a charge-coupled device video camera (FK6990;
Pieper, Schwerte, Germany) and transferred to a monitor (Trinitron;
Sony, Tokyo, Japan) and DVD system (DVD-HR775; Samsung, Eschborn,
Germany) for off-line evaluation.
Quantitative off-line analyses of the microscopic images were per-
formed using the software package CapImage (Zeintl, Heidelberg,
Germany). For this purpose, eight postcapillary or collecting venules
per chamber were randomly selected for the determination of leuko-
cyte–endothelial cell interaction, microhemodynamic parameters and
macromolecular leakage at baseline conditions 19 h before topical
exposure of the chamber tissue to TNF-α as well as 0.5 h, 2 h and 4 h
after TNF-α treatment.
Leukocytes were classiﬁed according to their interaction with the
microvascular endothelium as rolling or adherent cells [29]. Rolling leu-
kocyteswere deﬁned as cellsmovingwith a velocity less than two-ﬁfths
of the centerline velocity, and are given as number of cells per minute,
passing a reference point within the microvessel. Adherent leukocytesFig. 4.CK2 inhibition affects subcellular localization of p65. (A) Immunoﬂuorescence images ofH
CX-4945 (50 μM) or (Q) quinalizarin (50 μM) for 1 h or 5 h. P65 was detectedwith an anti-p65
DAPI. Scale bars: 20 μm. Images are representative of experiments conducted in triplicate. (B) H
analyzed byWestern blot analysis.Western blots are representative of experiments conducted i
as assessed by quantitative analysis of Western blots. Mean ± SEM. *P b 0.05 vs. vehicle.were deﬁned as cells that did not move or detach from the endothelial
lining within a 20 s observation period, and are given as number of
cells per square millimeter of endothelial surface. Endothelial surface
was calculated from the diameter and length of the vessel segment
studied, assuming a cylindrical vessel geometry.
Diameters, centerline red blood cell (RBC) velocity, volumetric blood
ﬂow, andwall shear rate were determined in those venules in which leu-
kocyte–endothelial cell interaction was analyzed. Diameters (d) were
measured in μmperpendicularly to the vessel path. Centerline RBC veloc-
ity (v) was analyzed by the computer-assisted image analysis system
using the line shift method [30]. Volumetric blood ﬂow was calculated
by Q = π ∗ (d ∕ 2)2 ∗ v ∗ 1.6 [pL/s], where 1.6 represents the Baker–
Wayland factor [31] to correct for the parabolic velocity proﬁle in
microvessels with diameters N20 μm. Additionally, wall shear rate
(y) was calculated based on the Newtonian deﬁnition: y = 8 ∗ v ∕ d.
Macromolecular leakage as a parameter ofmicrovascular permeabil-
ity and, thus, endothelial integrity was assessed after intravenous in-
jection of the macromolecular ﬂuorescent dye FITC-labeled dextran
150,000 by determining densitometrically gray levels in the tissue
directly adjacent to the venular vessel wall (E1), as well as in the
marginal cell free plasma layer within the vessel (E2). Extravasation
(E) was then calculated as E = E1 ∕ E2 [32].
At the end of the in vivo experiments, the animals were sacriﬁced
with an overdose of the anesthetic and the dorsal skinfold preparations
were excised for further immunohistochemical analyses.
2.17. Immunohistochemistry
Formalin-ﬁxed specimens of the dorsal skinfold chamber prepara-
tions were embedded in parafﬁn. For the analysis of transmigrated leu-
kocytes, 2 μm-thick sections were cut and stained with a polyclonal
rabbit anti-mouse antibody against the neutrophil granulocyte marker
myeloperoxidase (MPO) followed by biotinylated secondary goat anti-
rabbit IgG antibody. Sections solely incubated with the secondary anti-
body were used as negative controls. The sections were counterstained
with Mayer's hemalaun solution and examined by light microscopy
(BX60F). MPO-positive cells were assessed in 10 high power ﬁelds
(HPFs) per section.
2.18. Statistical analysis
After testing the data for normal distribution and equal variance, dif-
ferences between two groups were analyzed by the unpaired Student's
t-test and differences between multiple groups were analyzed by
ANOVA followed by the appropriate post hoc test, including correction
of the alpha error according to Bonferroni's probabilities (SigmaStat;
Jandel Corporation, San Rafael, CA, USA). To test for time effects in the
individual groups, ANOVA for repeated measures was applied followed
by the Bonferroni-t-test. All values are expressed as means ± SEM.
Statistical signiﬁcance was accepted for a value of P b 0.05.
3. Results
3.1. Effect of CX-4945 and quinalizarin on CK2 kinase activity and
cell viability
In a ﬁrst set of experiments, we analyzed the effect of the two inhib-
itors CX-4945 and quinalizarin on the CK2 kinase activity in endothelialDMEC,whichwere cultivatedwithout TNF-α, with TNF-α (10ng/mL) andDMSO (vehicle),
antibody and labeled by Cy3-conjugated secondary antibody. Cell nuclei were stainedwith
DMEC were treated for 5 h as described above and the subcellular localization of p65 was
n triplicate. (C andD) p65/α-tubulin (% of vehicle) (C) andp65/nucleolin (% of vehicle) (D),
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exposed to the indicated concentrations of CX-4945 (1–50 μM) or
quinalizarin (1–50 μM) in the presence of 10 ng/mL TNF-α for 5 h.
Both inhibitors decreased the activity of CK2 (Fig. 1A). Notably, the in-
hibitory effect of CX-4945 was more pronounced when compared to
quinalizarin. Western blot analyses of the cells further revealed that
the inhibition of CK2 activity by both compounds was not associated
with a reduced expression of the catalytic subunit CK2α of the holoen-
zyme (Fig. 1B). For the determination of cell viability after CK2 inhibi-
tion, we performed two different cytotoxicity assays, i.e. LDH and
WST-1 assays. For this purpose, HDMEC were identically treated as
described above. Under these conditions, inhibition of CK2 with CX-
4945 or quinalizarin did not affect the viability of the cells (Fig. 1C andD).
3.2. Effect of CK2 inhibition on surface protein expression of HDMEC
Fluorescence cytometry was performed to assess the expression of
PECAM-1, E-selectin, ICAM-1 and VCAM-1 on TNF-α-stimulated and
non-stimulated HDMEC, which were exposed to different concentra-
tions of the CK2 inhibitors CX-4945 or quinalizarin (Fig. 2A, C, E and
G).We found that PECAM-1 expression on HDMECwas neither affected
by TNF-α nor by TNF-α in combination with the two CK2 inhibitors
(Fig. 2B). In contrast, TNF-α signiﬁcantly increased the endothelial
expression of E-selectin, ICAM-1 and VCAM-1 (Fig. 2D, F and H). Of
interest, this effect of TNF-αwas diminished by CX-4945 and quinalizarin
(Fig. 2D, F and H), indicating that CK2 kinase activity is required for TNF-
α-induced up-regulation of E-selectin, ICAM-1 and VCAM-1 expression.
Noteworthy, treatment of HDMEC solely with the CK2 inhibitors CX-
4945 and quinalizarin did not affect the expression of PECAM-1, E-
selectin, ICAM-1 and VCAM-1 (data not shown).
To exclude that the observed effects of CX-4945 and quinalizarin on
the expression of E-selectin, ICAM-1 and VCAM-1 were primarily
caused by off target effects of the inhibitors, we additionally transfected
HDMEC with siRNA against CK2α and α′. In this control experiment,
silencing of CK2 reduced the levels of CK2α and α′ in the primary cells
to 55% and 69% of controls (Fig. 3A and B). The expression of E-selectin,
ICAM-1 and VCAM-1 was reduced to a similar extent (Fig. 3C–E).
3.3. Effect of CK2 inhibition on subcellular localization of p65 and
phosphorylated p65 and its transcriptional activity
The expression of E-selectin, ICAM-1 and VCAM-1 is controlled by
theNF-κBpathway.Moreover, the transcriptional activity of p65, a com-
ponent of this pathway, is strictly regulated by its shuttling from the
cytoplasm into the nucleus as well as its posttranscriptional modiﬁca-
tions. It has been shown that CK2 phosphorylates p65 on serine 529
and the loss of this phosphorylation decreases the transcriptional activ-
ity of p65 [14,33]. To determine whether inhibition of CK2 affects
shuttling of p65 between the cytoplasm and nucleus we analyzed its
subcellular localization 1 h and 5 h after TNF-α stimulation (Fig. 4A).
As expected, p65 was solely localized in the cytoplasm of unstimulated
HDMEC. Treatment of HDMEC for 1 h with TNF-α showed a transloca-
tion of p65 into the nucleus. After 5 h treatment we detected a partial
redistribution of p65 from the nucleus to the cytoplasm. Interestingly,
treatment of HDMEC with TNF-α and CX-4945 or quinalizarin elevatedFig. 5. CK2 inhibition affects phosphorylation of p65. (A) Immunoﬂuorescence images of HDMEC, w
(50 μM) or (Q) quinalizarin (50 μM) for 1 h or 5 h. Phopho-p65was detected with an anti-phosph
with DAPI. Scale bars: 20 μm. Images are representative of experiments conducted in triplicate. (B)
was analyzed byWestern blot analysis.Western blots are representative of experiments conducted
Western blots. Mean ± SEM. *P b 0.05 vs. vehicle. (D) Schematic representation of the integrated
luciferase open reading frame. The location of the NF-κB and Sp1 binding sites within the LTR is d
region of the 5′ LTR of the transfer vector is deleted. The locations of the woodchuck hepatitis vi
(E) RLU (% of vehicle) of HDMEC, which infected with a recombinant lentivirus encoding the N
48 h and afterward cultivated without TNF-α, with TNF-α (10 ng/mL) and DMSO (vehicle) or the
and analyzed for luciferase activities. Luciferase activity was normalized to the protein concentratiothe nuclear localization of p65 after 1 h and 5 h. This indicates that inhi-
bition of CK2 led to an accumulation of p65 in the nucleus. These ﬁndings
were conﬁrmed by additional Western blot analyses, quantifying the
cytoplasmatic and nuclear levels of p65 in quinalizarin- and CX-4945-
treated HDMEC after 5 h (Fig. 4B–D). To exclude that the inhibitors solely
affect the subcellular localization of p65,HDMECwere treated for 5 hwith
CX-4945 or quinalizarin. Under these conditions, p65 was mainly detect-
ed in the cytoplasm (data not shown).
To further clarifywhether the inhibition of CK2 affects thephosphor-
ylation of p65, HDMEC were treated as described above and phosphor-
ylated p65 was detected with phospho-speciﬁc antibodies against the
CK2 phosphorylation site serine 529 in the polypeptide chain of p65.
We found that quinalizarin and CX-4945markedly decreased the nucle-
ar signal of phosphorylated p65 in TNF-α-stimulated HDMEC when
compared to vehicle-treated controls (Fig. 5A–C).
Finally, we analyzed the transcription activity of the NF-κB complex
in HDMEC. We used lentiviral gene transfer to integrate a luciferase
reporter gene under the control of the HIV LTR into the chromatin of
HDMEC to ensure that the reporter gene is embedded into a nucleoso-
mal structure. The LTR contains two binding sites for NF-κB. A schematic
depiction of the integrated provirus is shown in Fig. 5D. In linewith pre-
vious results [33], the transcriptional activity of NF-κB was increased in
TNF-α-stimulated HDMEC when compared to untreated cells (Fig. 5E).
Moreover, NF-κB reporter activity was lower in HDMEC, which were
treatedwith TNF-α and CX-4945 or quinalizarin (Fig. 5E). Taken togeth-
er, these results indicate that inhibition of CK2 markedly decreased the
NF-κB gene expression in TNF-α-stimulated endothelial cells.
In control experiments, we analyzed the subcellular localization and
phosphorylation of p65 in siRNA-treated HDMEC. In line with our
experiments using the CK2 inhibitors, we found that CK2 silencing
also signiﬁcantly decreased the nuclear signal of phosphorylated p65
(Fig. 6A–E).
3.4. Effect of CK2 inhibition on leukocyte binding to endothelial cells in vitro
Because ICAM-1 and VCAM-1 mediate ﬁrm leukocyte adhesion to
the inﬂamed endothelium, we next examined the binding capacity of
leukocytes to quinalizarin- or CX-4945-treated HDMEC under TNF-α-
stimulation. For this purpose, HDMEC were treated without, with TNF-
α and vehicle or the indicated concentration of CX-4945 or quinalizarin
for 5 h and subsequently co-cultivated with MNC from whole blood for
1 h. As shown in Fig. 7A treatment of HDMEC with TNF-α increased
binding of MNC whereas CX-4945 (50 μM) or quinalizarin (50 μM)
decreased the binding capacity. Quantiﬁcation of bound MNC revealed
the inhibitory effect of the CK2 inhibitors on MNC binding to HDMEC
(Fig. 7B).
3.5. Effect of CK2 inhibition on leukocyte–endothelial cell interaction in vivo
The effect of CK2 inhibition by CX-4945 on leukocyte–endothelial
cell interaction was analyzed in postcapillary and collecting venules of
TNF-α-exposed dorsal skinfold chambers. For this purpose, we ﬁrst
assessed important microhemodynamic parameters of the analyzed
vessels. In linewith former studies [34,35], we found that TNF-α stimu-
lation increased the venular diameter and volumetric blood ﬂow whenhichwere cultivatedwithout TNF-α, with TNF-α (10 ng/mL) and DMSO (vehicle), CX-4945
o-p65 antibody and labeled by Cy3-conjugated secondary antibody. Cell nuclei were stained
HDMECwere treated for 5 h as described above and the nuclear localization of phospho-p65
in triplicate. (C) Phospho-p65/nucleolin (% of vehicle), as assessed by quantitative analysis of
provirus encoding an HIVLTR/luciferase reporter gene. The LTR sequence is upstream of the
epicted. Additionally the nucleotide sequences of the NF-κB binding sites are shown. The U3
rus posttranscriptional regulatory element (WPRE) and the HIV ﬂap element are indicated.
F-κB-responsive HIVLTR/luciferase reporter gene for 20 h. HDMEC were serum-starved for
indicated concentrations of CX-4945 or quinalizarin (Q) for 5 h. Cell extracts were prepared
n. Vehicle treated cellswere used as control and set 100%.Mean± SEM. *P b 0.05 vs. vehicle.
Fig. 7. CK2 inhibition reduces leukocyte–endothelial cell interaction in vitro.
(A) Immunoﬂuorescence images of leukocyte bound to HDMEC. HDMEC were
cultivated without TNF-α, with TNF-α (10 ng/mL) and DMSO (vehicle) or the indicated
concentrations of CX-4945 or quinalizarin (Q) for 5 h. Then, isolated MNC from whole
blood were stained with calcein-AM and co-cultured for 1 h with the treated HDMEC. After
washing, bound MNC were analyzed by immunoﬂuorescence. Scale bars: 400 μm.
(B) Quantitative analysis of (A). Vehicle-treated cells were used as control and set 100%.
Mean ± SEM. *P b 0.05 vs. vehicle.
Fig. 6. Inhibition of CK2 by siRNA affects subcellular localization and phosphorylation of p65.
(A) HDMECwere treatedwith siRNA against CK2α and CK2α′ or scrambled siRNA (control)
for 72 h. After HDMEC were stimulated with 10 ng/mL TNF-α for 5 h, the subcellular
localization of p65 was analyzed byWestern blot. Western blots are representative of experi-
ments conducted in triplicate. (B and C) p65/nucleolin (% of scr-siRNA) (B) and p65/α-tubulin
(% of scr-siRNA) (C), as assessed by quantitative analysis of Western blots. Mean ± SEM.
(D) HDMEC were treated as described above and the phosphorylation of p65 was assessed
by Western blot analysis. Western blots are representative of experiments conducted in
triplicate. (E) Phospho-p65/nucleolin (% of scr-siRNA), as assessed by quantitative analysis of
Western blots. Mean ± SEM. *P b 0.05 vs. scr-siRNA.
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observationperiod, however,wedid not detect any signiﬁcant differences
in diameter, centerline RBC velocity, wall shear rate and volumetric bloodﬂow of venules in CX-4945-treated and vehicle-treated control ani-
mals (Table 1). This indicates that the leukocyte–endothelial cell
interaction could be analyzed in both groups under comparable
microhemodynamic conditions.
TNF-α stimulation of the chamber tissue resulted in an elevated num-
ber of rolling and adherent leukocytes and a reduced functional capillary
density in CX-4945-treated and vehicle-treated control animals (Fig. 8A–
D). However, in line with our in vitro results, the numbers of adherent
leukocytes were signiﬁcantly lower in CX-4945-treated mice 0.5 h and
4 h after TNF-α treatment (Fig. 8C). This was associated with a markedly
decreased macromolecular leakage (Fig. 8E), indicating an improved
endothelial integrity. In an additional set of control experiments, animals
were solely treated with CX-4945 or vehicle without exposure to TNF-α.
Under these non-inﬂamed conditions, CX-4945 did not affect leukocyte–
endothelial cell interaction, functional capillary density andmacromolec-
ular leakage within the chamber tissue (Fig. S1).
Table 1
Diameter (μm), centerlineRBC velocity (μm/s),wall shear rate (s−1) and volumetric bloodﬂow(pL/s) of postcapillary and collecting venules indorsal skinfold chambers of CX-4945-treated and
vehicle-treated BALB/c mice 19 h before as well as 0.5 h, 2 h and 4 h after topical TNF-α application.
−19 h +0.5 h +2 h +4 h
Diameter (μm)
Vehicle 32.3 ± 2.4 37.2 ± 3.1 46.4 ± 3.8a 45.5 ± 3.3a
CX-4945 36.1 ± 2.3 39.3 ± 2.7 51.2 ± 3.9a 50.7 ± 4.2a
Centerline RBC velocity (μm/s)
Vehicle 407.8 ± 38.8 539.9 ± 110.8 451.3 ± 77.3 496.9 ± 72.1
CX-4945 455.5 ± 50.6 500.1 ± 62.8 425.2 ± 65.3 441.7 ± 74.2
Wall shear rate (s−1)
Vehicle 103.84 ± 10.8 115.3 ± 20.4 76.3 ± 12.4 87.7 ± 12.4
CX-4945 104.9 ± 14.5 104.4 ± 14.3 65.8 ± 6.4a 75.1 ± 16.3a
Volumetric blood ﬂow (pL/s)
Vehicle 227.1 ± 45.2 444.5 ± 149.8 581.3 ± 173.8b 573.7 ± 145.2b
CX-4945 302.2 ± 58.8 420.3 ± 105.1 645.1 ± 204.4b 638.7 ± 196.6b
Mean ± SEM.
a P b 0.05 vs.−19 h and +0.5 h in each individual group.
b P b 0.05 vs−19 h in each individual group.
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preparations 4 h after TNF-α exposure further exhibited a signiﬁcantly
reduced number of transmigrated MPO-positive leukocytes in CX-4945-
treated animals (5.3 ± 0.5/HPF) when compared to vehicle-treated con-
trols (10.5 ± 0.3/HPF).
4. Discussion
The interaction of leukocyteswith themicrovascular endothelium of
inﬂamed tissue is a highly dynamic process, which is tightly regulated
by a complex network of intracellular signaling pathways mediating
the expression of adhesion proteins on the surface of endothelial cells
and leukocytes [36]. In the present study, protein kinase CK2 was iden-
tiﬁed as a novel key regulator of this process. In fact, we could demon-
strate that inhibition of CK2 suppresses the transcriptional activity of
the NF-κB complex and down-regulates the expression of E-selectin,
ICAM-1 and VCAM-1. This is associated with a reduced leukocyte adhe-
sion to endothelial cells under TNF-α-induced inﬂammatory conditions.
During the last years, several studies reported that inhibition of CK2
selectively induces apoptosis in tumor cells relative to normal cells [37].
Accordingly, CK2 has been suggested as a potential therapeutic target
for the development of novel cancer drugs [38–42]. For this purpose,
a broad spectrum of CK2 inhibitors has been developed, including
quinalizarin and more recently CX-4945. By now, the latter one is con-
sidered to be the most speciﬁc CK2 inhibitor with a binding afﬁnity of
Ki = 0.38 nM [43]. In contrast, quinalizarin exhibits a binding afﬁnity
of Ki = 0.052 μM [38], which is comparable to that of other commonly
used CK2 inhibitors, such as 2-dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole (DMAT), tetrabromocinnamic acid (TBCA) and 4,5,6,7-
tetrabromo-1H-benzotriazole (TBB) [44–46]. Quinalizarin and CX-4945
have previously been shown to effectively reduce the activity of CK2 in
animal studies focusing on cancer [40,42] and endometriosis [19]. More-
over, CX-4945 has even successfully entered phase II clinical trials [47].
Therefore, we decided to use quinalizarin and CX-4945 to study the effect
of CK2 inhibition on the expression of adhesion molecules and on leuko-
cyte binding to endothelial cells in vitro.
A reduced CK2 activity in TNF-α-stimulated HDMEC resulted in a
decreased expression of the adhesion proteins E-selectin, ICAM-1 and
VCAM-1. The expression of these proteins is regulated by a combination
of several transcription factors, including NF-κB [13,48–52]. The NF-κB
pathway is a fundamental pathway in inﬂammatory processes. Down-
regulation of any member of this pathway results in a decreased inﬂam-
matory response. P65 is a key factor of the NF-κB pathway, whose tran-
scriptional activity or subcellular localization is crucially determined by
phosphorylation events [53–55]. In former studies, it has been shown
that CK2 phosphorylates p65 on serine 529 and that the loss of thisphosphorylation decreased the transcriptional activity of p65 [14,33]. In
the present study, we found that inhibition of CK2 by CX-4945 or
quinalizarin decreased the level of phosphorylated p65 as well as the ex-
pression of a luciferase reporter gene controlled byNF-κB binding sites. In
addition, we detected an accumulation of nuclear p65 in TNF-α-
stimulated HDMEC after CK2 inhibition. The inhibitor protein IκBα,
which is part of a negative feedback loop for terminating the activity of
NF-κB, is necessary for the rapid degradation of p65 after stimulation
[56]. Hochreiner et al. reported that hypo-phosphorylation leads to accu-
mulation of p65 in the nucleus due to a defective IκBα synthesis [57].
Thus, it is tempting to speculate that the loss of p65 phosphorylation by
CK2 prevents its shuttling from the nucleus into the cytoplasm by
down-regulation of this negative feedback loop resulting in nuclear p65
accumulation.
PECAM-1 is constitutively expressed on the surface of endothelial
cells [58,59]. On the other hand, NF-κB binding sites have been identi-
ﬁed in the promoter region of PECAM-1 [60], indicating that this protein
may be further up-regulated under inﬂammatory conditions. However,
we did not detect amarked effect on the expression of PECAM-1 in TNF-
α-stimulated HDMEC. These results are in line with a previous study of
Romer et al. [61], demonstrating that the expression of PECAM-1 is not
altered in human umbilical venular endothelial cells (HUVEC) in the
presence of TNF-α. In addition, we found that PECAM-1 expression on
HDMEC is not affected by the treatment with quinalizarin or CX-4945.
This shows that CK2 is not generally involved in the regulation of all
endothelial adhesion proteins, and, thus, is a promising candidate for
the selective targeting of speciﬁc cell–cell interactions.
ICAM-1 is a ligand for leukocyte adhesion protein (LFA)-1 [62],
whereas VCAM-1 interacts with integrin α4β1 on leukocytes [63]. Both
proteins speciﬁcally mediate ﬁrm leukocyte adhesion to the microvas-
cular endothelium. Accordingly, inhibition of CK2 by quinalizarin or
CX-4945 markedly decreased the number of bound MNC in our leuko-
cyte adhesion assay. To conﬁrm these in vitro results in vivo, we used
the dorsal skinfold chamber, which has been proven to be a suitable
model for the analysis of leukocyte–endothelial cell interaction under
physiological and inﬂammatory conditions by means of intravital ﬂuo-
rescence microscopy [27,28,64]. For this purpose, we repetitively
assessed the number of rolling and adherent leukocytes in postcapillary
and collecting venules of TNF-α-treated chambers. The endothelium of
these vessels typically acts as a gatekeeper to leukocyte adhesion and
transmigration into the surrounding tissue [65]. Because the interaction
of leukocytes and endothelial cells is dependent on intravascular blood
ﬂow and wall shear rates [66], we ﬁrst analyzed microhemodynamic
parameters of the vessels, which did not differ between CX-4945-
treated and vehicle-treated control animals. Under these standard-
ized microhemodynamic conditions, inhibition of CK2 by CX-4945
Fig. 8. Inhibition of CK2 reduces leukocyte adhesion in vivo. (A) Intravital ﬂuorescence microscopic images of postcapillary venules in dorsal skinfold chambers of CX-4945-treated and
vehicle-treated BALB/c mice 19 h before as well as 4 h after topical TNF-α application. Blue-light epi-illumination with contrast enhancement by staining of plasma with FITC-dextran
or green-light epi-illumination with staining of leukocytes (arrows)with rhodamine 6G. Scale bars: 50 μm. (B–E) Rolling leukocytes (min−1) (B), adherent leukocytes (mm−2) (C), func-
tional capillary density (cm−1) (D) and macromolecular leakage (E1/E2) (E) in dorsal skinfold chambers of CX-4945-treated and vehicle-treated BALB/c mice 19 h before as well as 0.5 h,
2 h and4 h after topical TNF-α application, as assessed by intravitalﬂuorescencemicroscopyand computer-assisted image analysis.Mean±SEM. *Pb 0.05 vs. vehicle. aP b 0.05 vs−19h in
each individual group; bP b 0.05 vs.−19 h and + 0.5 h in each individual group.
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the microvascular endothelium. However, we did not detect a difference
in numbers of rolling leukocytes despite our in vitro ﬁnding that CX-4945
suppresses the expression of E-selectin. This unexpected observationmay
be due to the fact that other members of the selectin family, such as P-
selectin, are coexpressed in inﬂamed tissue [67]. Studies indicate
that there is an overlapping function of these selectins in leukocyte
rolling [68]. Accordingly, they may have compensated the down-
regulation of E-selectin in the present experimental setting.
We additionally detected a markedly decreased number of
transmigrated leukocytes in CX-4945-treated chambers 4 h after stim-
ulation with TNF-α. This observation may be primarily due to thereduced expression of VCAM-1 after CK2 inhibition, because VCAM-1
does not only mediate ﬁrm leukocyte adhesion to endothelial cells,
but is also crucially involved in diapedesis [5]. Besides, there are some
evidences that CK2 phosphorylates proteins of the extracellular matrix,
such as vitronectin, which interacts with integrin αvβ3 on leukocytes
[69,70]. Integrin αvβ3, in turn, has also been shown to be involved in
the process of transmigration [71].
Phosphorylation of tight junction components is critically involved
in the regulation of tight junction assembly, maintenance and function.
Previous studies indicate that some of these components are substrates
of CK2 [72,73]. Thus, itmay be speculated that inhibition of CK2 disrupts
endothelial integrity. However, in the present study we observed a
2135E. Ampofo et al. / Biochimica et Biophysica Acta 1852 (2015) 2123–2136reduced macromolecular leakage in chambers of CX-4945-treated mice
when compared to vehicle-treated controls. A possible explanation for
this ﬁnding may be the beneﬁcial effect of CK2 inhibition on
leukocyte-mediated endothelial injury in our experimental setting of
TNF-α-induced tissue inﬂammation.
In conclusion, we have demonstrated that protein kinase CK2
regulates TNF-α-stimulated leukocyte–endothelial cell interaction. In
fact, inhibition of CK2 suppresses NF-κB gene expression by affecting
the phosphorylation state of p65 and its subcellular localization. This
down-regulates the expression of E-selectin, ICAM-1 and VCAM-1,
which is associated with a reduced leukocyte adhesion to endothelial
cells. Accordingly, CK2 represents a promising target for the develop-
ment of novel anti-inﬂammatory drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.07.013.
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